Drugs / Lenalomide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03601078 Background | Dec 2018 → Jan 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lenalomide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03601078 ↗ |